Key Takeaways:
PureTech Health plc announced its intention to voluntarily delist its American Depositary Shares from Nasdaq, with the last day of trading expected on or about May 20, 2026, to concentrate on its primary London Stock Exchange listing.
"We have determined that concentrating our listing on the London Stock Exchange is the most effective way to support our shareholders and execute our strategy," Robert Lyne, Chief Executive Officer of PureTech, said.
The decision follows a review showing the majority of trading volume, liquidity, and price discovery for PureTech's shares occurs on the LSE, where most of its investor base is also centered. Each American Depositary Share represents ten ordinary shares of the company. PureTech expects to file a Form 25 with the U.S. Securities and Exchange Commission to formally begin the delisting process on or about May 11, 2026.
The move is designed to reduce the significant costs and administrative demands of a dual listing, allowing PureTech to focus resources on its biotherapeutics portfolio. Following the delisting, the company expects its ADSs will be quoted and traded on the over-the-counter market through a sponsored Level 1 ADR program.
Following the delisting from Nasdaq, PureTech intends to file a Form 15F with the SEC to terminate its reporting obligations under the Securities Exchange Act of 1934. The company’s reporting obligations will be suspended immediately upon filing, and the termination is expected to become effective within 90 days, provided there are no objections from the SEC. No immediate action is required from ADS holders at this time.
The delisting simplifies PureTech's structure and may reduce overhead, but it could also limit visibility to a large pool of US investors. Shareholders will watch the transition to the OTC market and the stock's subsequent liquidity on the LSE.
This article is for informational purposes only and does not constitute investment advice.
